REVIEW ARTICLE
Prognostic significance of PD-L1 expression
in pancreatic cancer: evidence from an updated
meta-analysis
1
Department of Gastroenterology, Affiliated Hospital of Putian University, Putian, Fujian, P.R. China
2
Ophthalmology Department, Affiliated Hospital of Putian University, Putian, Fujian, P.R. China
3
Department of of Infectious Diseases, Jining No. 1 People’s Hospital, Jining, Shandong Province, P.R. China
4
Department of Neonatology, Jining No. 1 People’s Hospital, Jining, Shandong Province, P.R. China
Submission date: 2023-06-15
Final revision date: 2023-07-27
Acceptance date: 2023-08-16
Publication date: 2023-10-25
Corresponding author
Yingjie Shi
Prof. Yingjie Shi Department of Infectious Diseases, Jining No. 1 People’s Hospital, 6 Jiankang-road, Jining 272111, Shandong Province, China
Prof. Yingjie Shi Department of Infectious Diseases, Jining No. 1 People’s Hospital, 6 Jiankang-road, Jining 272111, Shandong Province, China
Xuan Sun
Xuan Sun Department of Neonatology, Jining No. 1 People’s Hospital, 6 Jiankang-road, Jining 272111, Shandong Province, China
Xuan Sun Department of Neonatology, Jining No. 1 People’s Hospital, 6 Jiankang-road, Jining 272111, Shandong Province, China
Pol J Pathol 2023;74(3):151-160
KEYWORDS
TOPICS
ABSTRACT
Recent studies revealed that programmed cell death ligand 1 (PD-L1) expression was associated with unfavorable prognosis in various solid tumors, but its clinical relevance for pancreatic cancer has not yet been well established. This meta-analysis summarizes the potential prognostic value of PD-L1 in pancreatic cancer. A quantitative meta-analysis was performed by a systematic search of databases including PubMed, EMBASE, Web of Science, Cochrane library, Scopus and Ovid for eligible studies on the prognostic significance of PD-L1 in pancreatic cancer patients. Pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated to evaluate the strength of the link between PD-L1 expression and clinical prognosis of patients. Seventeen eligible studies with 2669 patients were included in our study. A significant association was observed between PD-L1 abundance and poor overall survival (OS) of patients with pancreatic cancers, with a pooled hazard ratio (HR) of 1.902, 95% CI: 1.657-2.184. Sensitivity analysis confirmed the reliability of our results. Subgroup analysis shows that differences in regions and detection methods of PD-L1 did not change the overall predictive value of PD-L1 for poor prognosis in pancreatic cancer patients. This meta-analysis indicated that the expression of PD-L1 is associated with a worse OS in pancreatic cancer patients. Additionally, PD-L1 may act as a potential parameter for predicting poor prognosis and thus providing a promising target for anticancer therapy in pancreatic cancer.
REFERENCES (35)
1.
Jonathan DM, Rishi Surana, Juan WV, et al. Pancreatic cancer. Lancet 2020; 395: 2008-2020.
2.
Muraki T, Reid MD, Basturk O, et al. Undifferentiated Carcinoma With Osteoclastic Giant Cells of the Pancreas: Clinicopathologic Analysis of 38 Cases Highlights a More Protracted Clinical Course Than Currently Appreciated. Am J Surg Pathol 2016; 40: 1203-1216.
3.
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2016; 66: 7-30.
4.
Kadera BE, Toste PA, Wu N, et al. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Clin Cancer Res 2015; 21: 157- 165.
5.
Delitto D, Perez C, Han S, et al. Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. Cancer Immunol Immunother 2015; 64: 1553-1563.
6.
Dong H, Zhu G, Tamada K, et al. A third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369.
7.
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
8.
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
9.
Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
10.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
11.
Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13: 2151-2157.
12.
Wang L, Ma Q, Chen X, et al. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J Surg 2010; 34: 1059-1065.
13.
Chen Y, Sun J, Zhao H, et al. The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer. Onco Targets Ther 2014; 7: 1465-1472.
14.
Hutcheson J, Balaji U, Porembka MR, et al. Immunologic and metabolic features of pancreatic ductal adenocarcinoma define prognostic subtypes of disease. Clin Cancer Res 2016; 22: 3606-3617.
15.
Yamaki S, Yanagimoto H, Tsuta K, et al. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining. Int J Clin Oncol 2017; 22: 726-733.
16.
Zhuan-Sun Y, Huang F, Feng M, et al. Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis. Onco Targets Ther 2017; 10: 5005-5012.
17.
Hu Y, Chen W, Yan Z, et al. Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2019; 98: e14006.
18.
Imai D, Yoshizumi T, Okano S, et al. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Cancer Med 2017; 6: 1614-1626.
19.
Wang Y, Lin J, Cui J, et al. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer. Oncotarget 2017; 8: 9354-9365.
20.
Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
21.
Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012; 12: 9-12.
22.
Williamson PR, Smith CT, Hutton JL, et al. Aggregate data meta-analysis with time-to event outcomes. Stat Med 2002; 21: 3337-3351.
23.
Liang X, Sun J, Wu H, et al. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. Diagn Pathol 2018; 13: 5.
24.
Wang L, Ma Q, Li D, et al. Indoleamine 2,3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma. Pathol Res Pract 2018; 214: 1309-1314.
25.
Birnbaum DJ, Finetti P, Lopresti A, et al. Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget 2016; 7: 71198-71210.
26.
Diana A, Wang LM, D’Costa Z, et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016; 7: 40992-41004.
27.
Tsukamoto M, Imai K, Ishimoto T, et al. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Cancer Sci 2019; 110: 310-320.
28.
Danilova L, Ho WJ, Zhu Q, et al. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. Cancer Immunol Res 2019; 7: 886-895.
29.
Hrudka J, Lawrie K, Waldauf P, et al. Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature. Virchows Arch 2020; 477: 687-696.
30.
Iwatate Y, Hoshino I, Yokota H, et al. Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. Br J Cancer 2020; 123: 1253-1261.
31.
Li J, Yin L, Chen Y, et al. PD-L1 correlated gene expression profiles and tumor infiltrating lymphocytes in pancreatic cancer. Int J Med Sci 2021; 18: 3150-3157.
32.
Zhu Q, Qiao G, Huang L, et al. Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma. Front Oncol 2022; 12: 837560.
33.
Zhang Y, Chen X, Mo S, et al. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules. J Pathol Clin Res 2022; 8: 257-267.
34.
Tessier-Cloutier B, Kalloger SE, Al-Kandari M, et al. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer 2017; 17: 618.
35.
Fukunaga A, Miyamoto M, Cho Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004; 28: e26-e31.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
